|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The sensitivity and specificity of the HLA-B*5801 allele for prediction of allopurinol-induced SJS/TEN were 100 and 87%, respectively.
|
19696695 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 polymorphism was also strongly associated with the CBZ-SJS subgroup (OR: 152.089, 95% CI: 34.737-665.901) and significantly associated with the CBZ-SJS/TEN subgroup (OR: 13.993, 95% CI: 7.291-26.856).
|
29685430 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Due to the significant risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the use of carbamazepine is not recommended in patients carrying the human leukocyte antigen B (HLA-B) *15:02 allele.
|
28440597 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This has led to the recommendation that patients of Asian ancestry be tested for the HLA-B*1502 allele, in order to identify those at high risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis after administration of carbamazepine and, possibly, phenytoin and other antiepileptic drugs.
|
19262378 |
2009 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Available data also suggest that HLA-B*1502 is a risk allele for SJS/TEN caused by other aromatic AEDs with a similar structure to CBZ.
|
20001755 |
2010 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of HLA-B*15:02 and CYP2C9 *2 or *3 in the same patient increases the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis; hence, PHT should not be prescribed in these patients.
|
29636628 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We speculated that Korean individuals expressing the HLA-B*4403 allele may be highly susceptible to lamotrigine-induced SJS/TEN.
|
25327504 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent study demonstrated that HLA-B*1502 was a common risk allele in aromatic antiepileptic drugs (AEDs) induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
|
21169036 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 allele is associated with an increased risk of developing carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
|
31784043 |
2020 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
One hundred per cent of Han Chinese with SJS/TEN due to allopurinol have been found to be at least heterozygous for HLA-B*5801, the carriage rate for this allele in the Han Chinese population being about 15%.
|
21790926 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allopurinol is an efficacious urate-lowering therapy (ULT), but is associated with rare serious adverse drug reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), with higher risk among HLA-B*5801 carriers.
|
26554739 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A decision tree model was constructed to incorporate the real-world data on AED prescription patterns, incidences of AED-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), costs of AED treatments, SJS/TEN treatment, and HLA-B*15:02 testing, and quality of life.
|
26888992 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There is a strong relationship between the <i>HLA-B*1502</i> allele and carbamazepine-induced SJS and TEN in different Southeast Asian populations.
|
30018035 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, 17 of 49 patients with CM-SJS/TEN with SOC (34.7%) significantly harboured the HLA-B*44:03 and HLA-C*07:01 haplotype compared with only 11 of 159 healthy controls (6.9%) (OR=7.1, p=5.5×10<sup>-6</sup>).
|
29706602 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The associated haplotype is in linkage disequilibrium with the HLA-B*5801 allele known to be associated with allopurinol induced SJS/TEN in Asian populations.
|
21801394 |
2011 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This is a case control study to describe the clinical characteristics of SJS/TEN in Thai patients with neuropathic pain who were treated with CBZ, and to determine the association of HLA-B*1502 in these patients, comparing with those who exposed to CBZ for at least 6 months without any cutaneous reactions.
|
21676164 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) is strongly associated with HLA-B*58:01 in various populations including Japanese.
|
22277675 |
2012 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
19 DRESS and 67 SJS/TEN) and 182 allopurinol-tolerant patients were enrolled in the study.The HLA-B*58:01 allele was determined.
|
28509689 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
|
28062682 |
2017 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Results When persons having the HLA-B*1502 allele receive CBZ, the chance of developing SJS/TEN is as high as 88.1 %, while persons without the HLA-B*1502 allele do not develop SJS/TEN.
|
23649893 |
2013 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study demonstrates the genotype of HLA-B*59:01 in a patient with TEN associated with methazolamide treatment and thus supports the possible correlation between genetic background and methazolamide-associated SJS/TEN.
|
25970075 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine.
|
29392710 |
2018 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We developed a novel assay for the detection of the HLA-B*15:02 allele, which is robust, inexpensive and suitable for screening individuals of Asian ancestry in the prevention of CBZ-induced SJS/TEN.
|
27544047 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-B*44:03 was also detected as an independent risk allele for CM-, including AR-SJS/TEN with SOC.
|
24781922 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Individuals who carried the HLA-B*15:02-C*08:01 haplotype had a 14-fold higher risk for co-trimoxazole-induced SJS/TEN.
|
26086150 |
2015 |